Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998349 | 0.77 | ENPP2 (0.48) | ENPP2GRM2HTR2AHRH3 | |
| SCHEMBL2001798 | 0.76 | ENPP2 (0.51) | ENPP2GRM2HTR2APGRMEN1 | |
| SCHEMBL1998199 | 0.75 | ENPP2 (0.50) | ENPP2GRM2HTR2AMEN1KMT2A | |
| SCHEMBL1815295 | 0.73 | ENPP2 (0.53) | ENPP2 | |
| SCHEMBL839110 | 0.73 | ENPP2 (0.56) | ENPP2HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL1820132 | 0.72 | ENPP2 (0.48) | ENPP2HDAC1HDAC8HRH3 | |
| SCHEMBL839034 | 0.71 | ENPP2 (0.60) | ENPP2HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL839466 | 0.70 | ENPP2 (0.49) | ENPP2HTR2AHRH3 | |
| SCHEMBL1997408 | 0.70 | ENPP2 (0.49) | ENPP2MEN1KMT2AHRH3 | |
| SCHEMBL1999482 | 0.70 | ENPP2 (0.48) | ENPP2MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | OPRM1, OR10J3, OPRD1 | ENPP2 1556/4885GRM2 115/4885HTR2A 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.